Last reviewed · How we verify
MEDI3726 & Enzalutamide Combo — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
MEDI3726 & Enzalutamide Combo (MEDI3726 & Enzalutamide Combo) — MedImmune LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MEDI3726 & Enzalutamide Combo TARGET | MEDI3726 & Enzalutamide Combo | MedImmune LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MEDI3726 & Enzalutamide Combo CI watch — RSS
- MEDI3726 & Enzalutamide Combo CI watch — Atom
- MEDI3726 & Enzalutamide Combo CI watch — JSON
- MEDI3726 & Enzalutamide Combo alone — RSS
Cite this brief
Drug Landscape (2026). MEDI3726 & Enzalutamide Combo — Competitive Intelligence Brief. https://druglandscape.com/ci/medi3726-enzalutamide-combo. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab